科倫藥業漲停,控股子公司向默沙東授權7個在研ADC項目
格隆匯12月23日丨科倫藥業漲停,報價23.98元,市值339.79億元。科倫藥業昨晚公吿,科倫博泰將其管線中七種不同在研臨牀前ADC候選藥物項目以全球獨佔許可或獨佔許可選擇權形式授予默沙東在全球範圍內或在中國大陸、香港和澳門以外地區進行研究、開發、生產製造與商業化。科倫博泰保留部分授予獨佔許可的項目和有權保留授予獨佔許可選擇權的項目在中國大陸、中國香港和中國澳門研究、開發、生產製造和商業化的權利。《合作協議》生效後,科倫博泰將收到一次性合計1.75億美元不可退還的首付款。默沙東另將根據各項目開發階段及商業化進展分期向科倫博泰支付里程碑付款,並對上市產品按淨銷售額分層支付提成。如科倫博泰決定將全部授予獨佔許可選擇權項目全球權益授權給默沙東,預計會收到默沙東里程碑付款合計不超過93億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.